The Readout Loud

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?

Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?

Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?

Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?